user
menu
letter
Sign InRegister
langEnglisharrow
1/10
+7 View all
COADS MSDS

GMP Human Thrombopoietin Protein

DMF
Premium grade (Pre-GMP) version THN-H5216 is now available for seamless transition.
1/10
+7 View all
COADS MSDS
Cat. No. / Size
Price
Availability
Qty
GMP-THNH25-50ug
$985.00
In Stock - Delivery in 1-2 business days
GMP-THNH25-1mg (50ug X 20)
$7,730.00
Inquire about delivery time
GMP-THNH25-10mg (50ug X 200)
$54,110.00
Inquire about delivery time
GMP-THNH25
Sub-Total :
$ 0
Customize Product Request Quote
Contact Us
Contact Us
Sub-Total:
$ 0
Request Quote
Product Details
Performance Data
Reviews & Citations
Important Statement
Resources
  • Product Details
  • Performance Data
  • Reviews & Citations
  • Important Statement
  • Resources
Product Details

TPO (Thrombopoietin)​ is the primary regulator of megakaryocyte production and platelet formation, and also plays a fundamental role in HSC maintenance and expansion. In HSC culture, TPO promotes HSC quiescence, self-renewal, and long-term repopulating capacity. In iPSC-derived hematopoiesis, TPO acts at later stages of hematopoietic progenitor maturation and supports the maintenance of multipotent progenitors with engraftment potential.

Product Features and Advantages
  • Specific HSC Expansion Driver​: Efficiently supports hematopoietic stem cell expansion and hPSC‑derived hematopoietic stem and progenitor cell differentiation, validated in multiple clinical trials and cell manufacturing processes.
  • Reliable Large-Scale Supply: Ensures batch production capacity, supporting robust and consistent manufacturing scale-up.
  • High Lot-to-Lot Consistency​: Ensures reliable and reproducible performance in every batch, supporting scalable applications.
GMP Platform Advantages
  • Quality Assurance: Global QMS with comprehensive and stringent QC release criteria.
  • End-to-End GMP Compliance: Full manufacturing and QC under a cGMP system.
  • Comprehensive Control of Adventitious Agents: Stringent biosafety from cell banks to final release.
  • Comprehensive Regulatory Support: Includes RSF and DMF to meet global requirements.
  • Resilient Supply Chain: Intelligent modular facilities ensure a stable global supply.
  • Professional Support: Extensive manufacturing and application expertise to accelerate development.
Source

GMP Human Thrombopoietin Protein (GMP-THNH25) is expressed from human 293 cells (HEK293). It contains AA Ser 22 - Gly 353 (Accession # P40225-1).

Molecular Characterization
Other Tags and Version Biotin & Other Labeled Version

This protein carries no "tag".

The protein has a calculated MW of 35.5 kDa. The protein migrates as 75 kDa±5 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

N-terminal Sequence Analysis

Ser-Pro-Ala-Pro-Pro-Ala-Cys-Asp-Leu-Arg-Val-Leu-Ser-Lys-Leu
(Routinely tested)

Endotoxin

Less than 10 EU/mg, tested by the LAL method in compliance with USP <85> and Ph. Eur. 2.6.14.

Host Cell Protein

<0.5 ng/µg of protein tested by ELISA.

Host Cell DNA

<0.02 ng/μg of protein tested by qPCR.

Sterility

Sterility testing was performed using the membrane filtration method in compliance with USP <71> and Ph. Eur. 2.6.1.

Mycoplasma

Negative

Purity

>95% as determined by SDS-PAGE.

Formulation

Lyophilized from 0.22 μm filtered solution in 20 mM NaAc-HAc, pH5.0 with protectants.

Contact us for customized product form or formulation.

Vial Specification

2R (13 mm neck finish)

Shipping and Storage

This product is supplied and shipped on blue ice.

Upon receipt, store it immediately at -20°C or lower for long term storage.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:
  • -20°C to -70°C for 5 years in lyophilized state;
  • -70°C for 12 months under sterile conditions after reconstitution.
ACRO Quality Management System

Background

Thrombopoietin (Tpo), is a key regulator of megakaryocytopoiesis and thrombopoiesis. It is principally produced in the liver and is bound and internalized by the receptor Tpo R/c-mpl. Defects in the Tpo-Tpo R signaling pathway are associated with a variety of platelet disorders (1-3). The 353 amino acid (aa) human Tpo precursor is cleaved to yield the 332 aa mature protein. Mature human Tpo shares approximately 70% aa sequence homology with mouse and rat Tpo. It is an 80‑85 kDa protein that consists of an N‑terminal domain with homology to Erythropoietin (Epo) and a C‑terminal domain that contains multiple N‑linked and O-linked glycosylation sites (4, 5). Tissue specific alternate splicing of human Tpo generates multiple isoforms with internal deletions, insertions, and/or C‑terminal substitutions (6). Tpo promotes the differentiation, proliferation, and maturation of MK and their progenitors (4, 5, 7). Several other cytokines can promote these functions as well but only in cooperation with Tpo (8, 9). Notably, IL-3 independently induces MK development, although its effects are restricted to early in the MK lineage (8, 9). Tpo additionally promotes platelet production, aggregation, ECM adhesion, and activation (10-13). It is cleaved by platelet-derived thrombin following Arg191 within the C‑terminal domain and subsequently at other sites upon extended digestion (14). Both full length Tpo and shorter forms circulate in the plasma, with the shorter, N‑terminal EPO-like domain forms showing significantly increased specific activity (4, 5, 15). The C‑terminal domain is not required for binding to Tpo R or inducing MK growth and differentiation (5). Aside from its hematopoietic effects, Tpo is expressed in the brain where it promotes the apoptosis of hypoxia-sensitized neurons and inhibits neuronal differentiation by blocking NGF induced signaling (16, 17).